<DOC>
	<DOCNO>NCT02147886</DOCNO>
	<brief_summary>- This exploratory , randomize , parallel-group , dose escalation dose-controlled study without placebo arm . - Eligible patient randomize 1:1 ratio ( double-blind ) receive Cabaletta 2 dos , weekly 22 week ( total 24 week treatment ) .</brief_summary>
	<brief_title>Study To Assess Safety , Tolerability Efficacy Intravenous Cabaletta Patients With Machado-Joseph Disease</brief_title>
	<detailed_description />
	<mesh_term>Spinocerebellar Ataxias</mesh_term>
	<mesh_term>Spinocerebellar Degenerations</mesh_term>
	<mesh_term>Machado-Joseph Disease</mesh_term>
	<criteria>1 . Men woman , 18 75 year 2 . Clinically diagnosed MachadoJoseph disease/Spinocerebellar ataxia 3 confirm genetic test 3 . With disease stage 2 less 4 . Stable dos medication 30 day prior study entry duration study . 5 . Body Mass Index ( BMI ) â‰¤32 kg/m2 . 6 . Ability ambulate without assistance 1 . Diabetes mellitus type 1 2 2 . Other major disease 3 . Uncontrolled heart disease , chronic heart failure ( CHF ) . 4 . Other neurological disease . 5 . Ataxia derive cause geneticallyconfirmed spinocerebellar ataxia 6 . Presence psychosis , bipolar disorder , untreated depression 7 . History malignancy ( except noninvasive skin malignancy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Bioblast , Randomized , parallel-group , dose-controlled</keyword>
</DOC>